Internal Reference Number: FOI_7249
Date Request Received: 19/06/2023 00:00:00
Date Request Replied To: 21/06/2023 00:00:00
This response was sent via: By Email
Request Summary: Melanoma & RCC
Request Category: Researcher
| Question Number 1: How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma : • Avelumab + Axitinib • Axinitib • Cabozantinib • Everolimus • Ipilimumab montherapy • Lenvantinib + Everolimus • Nivolumab monotherapy • Nivolumab + Cabozantinib • Nivolumab + Ipilimumab • Pazopanib • Pembrolizumab + Axitinib • Pembrolizumab + Lenvatinib • Pembrolizumab monotherapy • Radiotherapy only • Sunitinib • Temsirolimus • Tivozanib • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: We do not treat these tumour groups at this Trust, patients receive their treatment at UHS. | |
| Question Number 2: How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) : • Cobimetinib • Dabrafenib • Dabrafenib AND Trametinib • Dacarbazine • Encorafenib AND Binimetinib • Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib AND Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: We do not treat these tumour groups at this Trust, patients receive their treatment at UHS. | |
| Question Number 3: Does you trust participate in any clinical trials for the treatment of Melanoma? If so please provide the name of each trial and number of patients that are taking part? | |
| Answer To Question 3: No n/a | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
